First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Introduction: Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard of care for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the second-line treatment after the failure of immunotherapy-based first-line remains elusive. Taking into account the w...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Giuseppe Cabibbo, Maria Reig, Ciro Celsa, Ferran Torres, Salvatore Battaglia, Marco Enea, Giacomo Emanuele Maria Rizzo, Salvatore Petta, Vincenza Calvaruso, Vito Di Marco, Antonio Craxì, Amit G. Singal, Jordi Bruix, Calogero Cammà
Format:	article
Langue:	EN
Publié:	Karger Publishers 2021
Sujets:	hepatocellular carcinoma sequential treatment immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/49f9c3951aad466793506f22ced773ef
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Documents similaires